Alleviating Effect of Lafutidine on Toxicity of S-1: Adjuvant Chemotherapy of Gastric Cancer (AEOLUS) - Alleviating Effect of Lafutidine on Toxicity of S-1: Adjuvant Chemotherapy of Gastric Cancer (AEOLUS)

Pharma Valley Center , Shizuoka Industrial Foundation0 个研究点目标入组 200 人开始时间: 2009年11月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patient with active double cancer (synchronous double cancer and metachronous double cancer), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 2) Patient with administration contraindication of S-1 and Lafutidine 3) Patient with regular use of H2-blocker, PPI, furucytocin, fenytoin, or warfarin. 4) Patients with the past history of severe allergic reactions. 5) Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 6) Severe watery diarrhea. 7) pregnant or nursing patient or with intent to bear baby 8) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.

发起方

Pharma Valley Center , Shizuoka Industrial Foundation